在接受阿克塔尔凝治疗的患者中使用皮质类固醇的使用和坚持,以治疗先进的类固醇症
Kyle Hayes1, John Niewoehner1, J Bradford Rice2
1Mallinckrodt Pharmaceuticals, Bridgewater, NJ, USA.
Advances in therapy
|September 20, 2023
概括
与其他治疗方法相比,Acthar Gel有效地减少了类固醇患者的皮质类固醇使用. 对Acthar Gel治疗的更高的坚持与皮质类固醇负担的更大降低相关,改善了患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 在免疫媒介疾病中长期使用皮质类固醇会增加不良事件并降低生活质量.
- 慢性高剂量皮质类固醇治疗与更高的医疗保健资源利用率和成本有关.
- 艾克塔尔凝 (储存型皮质激素注射) 显示出作为治疗沙丘症的类固醇节约剂的前景.
研究的目的:
- 为了比较Acthar Gel的皮质类固醇节约效果与萨尔科伊多सिस的替代治疗方法.
- 评估Acthar Gel对降低皮质类固醇负担的影响.
- 评估Acthar Gel粘附水平与降低皮质类固醇剂量之间的关系.
主要方法:
- 对大型行政药房和医疗索赔数据库 (2014-2020年) 的回顾性分析.
- 纳入标准: Sarcoidosis 诊断,≥2 Acthar 凝或比较性声明 (JAKi/rituximab),年龄≥18,12个月前后指数覆盖.
- 结果被测量为与基线的变化;Acthar Gel的坚持是根据所覆盖天数的比例来确定的.
主要成果:
- 阿克塔尔凝队列 (n=735) 的基线上皮质类固醇使用率 (80%) 比比较者 (n=626,56%) 高.
- 与同类药物相比,使用Acthar Gel导致任何类皮质类固醇的使用减少 (-9.0%对比 -3.2%) 和使用时间延长 (-10.0%对比 -3.0%).
- 较高的Acthar Gel粘附与较大的皮质类固醇减少相关 (任何使用的-11.2% vs. -6.1%,延长使用的-11.6% vs. -7.6%).
结论:
- 艾克塔尔凝显示,与类固醇的替代疗法相比,具有显著的皮质类固醇节约作用.
- 改善对Acthar Gel的坚持与更显著的皮质类固醇暴露减少有关.
- 阿克塔尔凝提供了一种可行的选择,用于降低患有沙尔科病的患者的皮质类固醇负担.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
295
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
295
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
01:26COPD: Management Using Bronchodilators and Corticosteroids
241
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
241
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
01:17Pericarditis III: Medical Management
13
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
13